Want to see TSE:VM full AI Analyst Report?
Voyageur Pharmaceuticals (VM) AI Stock Analysis
Voyageur Pharmaceuticals
(TSXV:VM)
The overall score of 42 reflects profound fundamental risks, primarily driven by a severe lack of profitability, heavy cash burn, and looming equity dilution. While the balance sheet is highly conservative with negligible debt and technicals show minor long-term support, the early-stage commercialization profile and deeply negative earnings present substantial downside risks for investors.
Voyageur Pharmaceuticals (VM) vs. iShares MSCI Canada ETF (EWC)
- Market Cap
- CAD 4.53M
- Dividend Yield
- ―
- Average Volume (3M)
- 155.59K
- Price to Earnings (P/E)
- -5.5
- Beta (1Y)
- 0.14
- Revenue Growth
- 360.63%
- EPS Growth
- 14.21%
- Country
- Canada
- Employees
- 49
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Drug Manufacturers - Specialty & Generic
Voyageur Pharmaceuticals Business Overview & Revenue Model
Company Description
Voyageur Pharmaceuticals Ltd. specializes in the creation of mineral-based active pharmaceutical ingredients (APIs). The company aims to produce radiocontrast agents utilizing barium and iodine, along with pharmaceutical products derived from bromine...
Voyageur Pharmaceuticals Financial Statement Overview
Summary
Minimal revenue generation and severe cash burn overshadow a nearly debt-free balance sheet. Widening net losses and rapid equity depletion expose the company to high liquidity risks and potential shareholder dilution.
Income Statement
15Very NegativeBalance Sheet
45NeutralCash Flow
10Very Negative| Breakdown | TTM | Feb 2026 | Feb 2025 | Feb 2024 | Feb 2023 | Feb 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 47.24K | 11.69K | 0 | 0 | 0 | 0 |
| Gross Profit | -2.17M | -1.22M | -1,570 | -2,185 | -2,908 | -2,246 |
| EBITDA | -3.80M | -3.53M | -1.71M | -1.22M | -1.74M | -2.05M |
| Net Income | -3.80M | -3.53M | -1.71M | -1.40M | -1.75M | -2.05M |
Balance Sheet | ||||||
| Total Assets | 3.22M | 3.11M | 2.60M | 2.16M | 2.10M | 2.57M |
| Cash, Cash Equivalents and Short-Term Investments | 441.87K | 267.05K | 165.57K | 2,085 | 31.56K | 812.97K |
| Total Debt | 40.00K | 40.00K | 40.00K | 40.00K | 25.52K | 42.08K |
| Total Liabilities | 2.81M | 1.85M | 2.15M | 727.88K | 630.83K | 660.64K |
| Stockholders Equity | 408.20K | 1.25M | 449.96K | 1.44M | 1.46M | 1.91M |
Cash Flow | ||||||
| Free Cash Flow | -1.01M | -2.89M | -302.29K | -991.25K | -2.00M | -2.09M |
| Operating Cash Flow | -1.01M | -2.89M | -302.29K | -991.25K | -1.72M | -1.65M |
| Investing Cash Flow | -272.31K | -270.02K | -165.96K | -174.72K | -274.15K | -432.08K |
| Financing Cash Flow | 1.35M | 3.26M | 631.73K | 1.14M | 1.21M | 2.90M |
Voyageur Pharmaceuticals Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:VM, the sentiment is Negative. The current price of 0.13 is below the 20-day moving average (MA) of 0.13, below the 50-day MA of 0.15, and below the 200-day MA of 0.13, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 42.10 is Neutral, neither overbought nor oversold. The STOCH value of 16.67 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:VM.
Voyageur Pharmaceuticals Peers Comparison
Overall Rating
TSE:LABS49Neutral
TSE:ROMJ45Neutral
TSE:INNO44Neutral
TSE:PCLO42Neutral- TSE:VM42Neutral
TSE:AVCN41Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| TSE:LABS | 49Neutral | CAD 27.77M | -5.60 | -13.79% | ― | -6.74% | 43.54% |
| TSE:ROMJ | 45Neutral | CAD 25.34M | -15.24 | -4.00% | ― | 16.66% | -1007.41% |
| TSE:INNO | 44Neutral | CAD 8.55M | -6.57 | -19.37% | ― | -19.20% | 42.54% |
| TSE:PCLO | 42Neutral | CAD 9.34M | -2.67 | 28.59% | ― | 0.90% | 57.73% |
| TSE:VM | 42Neutral | CAD 27.16M | -5.53 | -403.29% | ― | 360.63% | 14.21% |
| TSE:AVCN | 41Neutral | CAD 14.11M | -3.24 | -108.44% | ― | -0.23% | -142.54% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| TSE:VM | Voyageur Pharmaceuticals Ltd. | 0.12 | -0.04 | -25.00% | |
| TSE:LABS | Medipharm Labs (Otc) | 0.07 | -0.01 | -13.33% | |
| TSE:PCLO | Pharmacielo | 0.05 | 0.01 | 11.11% | |
| TSE:ROMJ | Rubicon Organics | 0.38 | -0.13 | -25.00% | |
| TSE:AVCN | Avicanna Inc | 0.10 | -0.16 | -60.38% | |
| TSE:INNO | Innocan Pharma Corporation | 1.90 | -16.10 | -89.44% |
Voyageur Pharmaceuticals Corporate Events
Voyageur Pharmaceuticals Converts Debt to Equity to Preserve Cash and Advance Contrast Media Strategy
PositiveVoyageur Pharmaceuticals has completed a shares-for-debt settlement totaling $192,300, issuing common shares at a deemed price of $0.155 to an officer and other creditors in order to preserve cash resources. The transaction, which received final acce...
Voyageur Pharmaceuticals Converts Debt to Equity to Preserve Cash
PositiveVoyageur Pharmaceuticals Ltd., a Canadian developer of barium and iodine contrast media for medical imaging, is pursuing a vertically integrated model in the radiology drug market. Leveraging its fully owned Frances Creek barium sulfate resource and...
Voyageur advances high-purity iodine extraction with field pilot plans
PositiveVoyageur Pharmaceuticals has advanced its proprietary Mueller iodine extraction process, achieving laboratory production of iodine at 99.8% purity with overall recovery above 90%. The company has established a dedicated lab and fabrication site in Ho...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Oct 21, 2026